Pemetrexed disodium for the treatment of malignant pleural mesothelioma: A systematic review and economic evaluation

Health Technology Assessment

Volumn 11, Issue 1, 2007, Pages

  Dundar, Y ^a   Bagust, A ^b   Dickson, R ^a   Dodd, S ^a   Green, J ^c   Haycox, A ^b   Hill, R ^a   McLeod, C ^a   Walley, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDROAZACITIDINE; ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PIRARUBICIN; TAMOXIFEN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ANEMIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPHAGIA; DYSPNEA; ECONOMIC EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOCYTE; LEUKOPENIA; LIFE EXPECTANCY; LUNG TOXICITY; META ANALYSIS; MONOTHERAPY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL; PLEURA MESOTHELIOMA; PRACTICE GUIDELINE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; MESOTHELIOMA; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; CISPLATIN; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GLUTAMATES; GREAT BRITAIN; GUANINE; HUMANS; MESOTHELIOMA;

EID: 33847382308     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11010     Document Type: Review

References (78)

1. Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology 2005; 10:2-8.
2. Cavazza A, Travis LB, Travis WD, Wolfe JT III, Foo ML, Gillespie DJ, et al. Post-irradiation malignant mesothelioma. Cancer 1996;77:1379-85.
3. Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogcnicity. Proc Natl Acad Sci USA 2000; 97:10214-19.
4. Cancerbacup. Mesothelioma information centre. URL: http://www.cancerbactip.org.uk/Cancertype/Mesothelioma. Accessed 2 August 2005.
5. Kaplan, NM, Palmer BF, Hughes RS. Malignant pleural mesothelioma. Am J Med Sci 2005; 329:29-44.
6. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-93.
7. Wan Y. Pemetrexed (Alimta) for malignant pleural mesothelioma. APC/DTC Briefing. London and South East Medicines Information Service on behalf of the London New Drugs Group. URL: http://www.druginfozone.nhs.uk/ new_drugs. Accessed September 2005.
8. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
9. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
10. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
11. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the UK. Thorax 2001;56:250-65.
12. Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
13. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
14. Van Gelder T, Damhuis R, Hoogsteden H. Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J 1994;7:1035-8.
15. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004; 126:1318-29.
16. Sterman D, Albelda S. Advances in the diagnosis, evaluation and management of malignant pleural mesothelioma. Respirology 2005;10:266-83.
17. NICE. Health Technology Appraisal: pemetrexed disodium for the treatment of malignant pleural mesothelioma. Comments on behalf of the Royal College of Physicians, Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology. London: NICE; 2005.
18. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004; 45 (Suppl):S103-19.
19. Thödtmann R, Depenbrock H, Durnez H, Blatter J, Johnson RD, van Oosterom A, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16.
20. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A Phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988;6:223-6.
21. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711-12.
22. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma. Evidence summary report #7-14-1 (Program in evidence-based care. A Cancer Care Ontario program). Toronto, Ontario; 2004.
23. van Meerbeeck JP, Manegold C, Gaafar R, van Klaveren RJ, Vincent M, Legrand C. A randomized Phase III trial of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an Intergroup study of the EORTC Lung Cancer Group and NCIC (abstract). J Clin Oncol 2004;22 (14 Suppl):A7021.
24. Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milieron B, Blanchon F, et al. A prospective study of detorubicin in malignant mesothelioma. Cancer 1985;56:2170-4.
25. 12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61.
26. Middleton GW, Smith IE, O'Brien MER, Norton A, Hickish T, Priest K, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269-73.
27. Eli Lilly and Company Limited. Manufacturer submission to the National Institute for Health and Clinical Excellence (pemetrexed disodium for the treatment of malignant pleural mesothelioma). London: NICE; 2005.
28. Muers MF, Rudd RM, O'Brien ME, Qian W, Hodson A, Parmar MK, et al. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma. Thorax 2004;59:144-8.
29. Stephens R, Hopwood P, Dirling D, Machin D. Randomised trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-36.
30. Fincham L, Copp G, Caldwell K, Jones L, Tookman A. Supportive care: experiences of cancer patients. Eur J Oncol Nurs 2004;9:258-68.
31. Willard C, Luker K. Supportive care in the cancer setting: rhetoric or reality? Palliat Med 2005; 19:328-33.
32. Department of Health. NHS cancer plan. London: HMSO; 2000.
33. Gysels M, Higginson I, Rajasekaran M, Davies E, Harding R. Improving supportive and palliative care for adults with cancer. London: King's College London; 2003.
34. Electronic Medicines Compendium (Summaries of Product Characteristics (SPCs). Alimta 500 mg powder for concentrate for solution for infusion [eMC entry]. Electronic Medicines Compendium 2004. URL: http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid= 15513. Accessed 11 November 2005.
35. European Medicines Agency. Summary of product characteristics (Annex I). URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/alimta/H-564-PI-en.pdf. Accessed 11 November 2005.
36. Hazarika M, White RM, Booth BP, Wang YC, Lee Ham DY, Cheng YL, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005;11:982-92.
37. Khan K, ter Riet G, Glanville J, Sowdon A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRD's guidance for carrying out or commissioning reviews. CRD Report No. 4. 2nd ed. York: Centre for Reviews and Dissemination, University of York; 2001.
38. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMI Economic Evaluation Working. BMJ 1996;313:275-83.
39. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
40. Gralla RJ, Hollen PJ, Liepa AM, Symanowski JT, Boyer MJ, Abraham R, et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-Meso instrument. Proc Am Soc Clin Oncol 2003;22:621 (abstract no. 2496).
41. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004;9:482-8.
42. Favaretto A. Overview on ongoing or planned clinical trials in Europe. Lung Cancer 2005; 49 Suppl 1:S117-21.
43. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma. Curr Opin Oncol 2003;15:148-56.
44. Milward M, Clarke S, Beale P, Boyer M, Childs A, Bishop J, et al. Phase I trial of pemetrexed (Alimta) and vinorelbine in patients with advanced cancer (abstract no. 2102). American Society of Clinical Oncology (ASCO) Annual Meeting, 2001.
45. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, et al. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000; 18:1748-57.
46. Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44.
47. Janne PA, Simon GR, Langer RN, Taub RN, Dowlati A, Fidias P, et al. An update of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM): a Phase II clinical trial. American Society of Clinical Oncology (ASCO) Annual Meeting, 2005; Abstract No. 7067.
48. Ceresoli GL, Zucali PA, Favaretto A, Marangalo M, Del Conte G, Ceribelli A, et al. A Phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma (MPM). Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2005.
49. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600.
50. 12 and folate reduce toxicity of pemetrexed, a novel antifolate antometabolite (abstract). Proc Soc Clin Oncol 2001; 20:300.
51. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
52. 12 supplementation on risk-benefit ratio from Phase III study of pemetrexed + csiplatin versus cisplatin in malignant pleural mesothelioma (abstract). Proc Am Soc Clin Oncol 2003;22:667.
53. Boyer M, Jassem J, Liepa A. Symptom and quality of life advantages for pemetrexed plus cisplatin versus cisplatin in the treatment of MPM. Presented at the 10th World Conference on Lung Cancer, 10-14 August 2003, Vancouver, BC.
54. Davey P, Cordony A, Rajan N, Arora B, Pavlakis N. Value for money of pemetrexed plus cisplatin versus cisplatin alone in the treatment of MPM. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference, 2004.
55. Australian Government Department of Health and Ageing. Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2005 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS). URL: http://www.health.gov.au/internet/wcms/publishing.nsf/ Content/pbacrec-mar05-neg1. Accessed October 2005.
56. Drummond M, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
57. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003;95:222-9.
58. BNF 50. British National Formulary [electronic resource]. London: British Medical Association, Royal Pharmaceutical Society. URL: http://bnf.org/. Accessed 28 November 2005.
59. MIMS. Monthly index of medical specialities. London: Haymarket Medical Publications; May 2005.
60. Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer 1986;58:1540-51.
61. Chailleux E, Dabouis G, Pioche D, De Lajartre M, De Lajartre AY, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest 1988;93: 159-62.
62. Tammilehto L, Maasilta P, Kostiainen S, Appelqvist P, Holsti LR, Mattson K. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration 1992;59:129-35.
63. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
64. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525-30.
65. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Program. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. URL: www.seer.cancer.gov. Accessed 10 November 2005.
66. van Meerbceck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
67. Planting AS, Schellens JH, Goey SH, van der Burg ME, de Boer-Dennert M, Stoter G, et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994;5:373-4.
68. Rebattu P, Merrouche Y, Blay JY, Martin C, Riou R, Perrin-Fayolle M. Phase IIstudy of very high dose cisplatin in the treatment of malignant mesothelioma. Eur Respir Rev 1993;3:226-8.
69. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21.
70. Andreopoulou E, Ross PJ, O'Brien ME, Ford HE, Priest K, Eisen T, et al. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004;15:1406-12.
71. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912-17.
72. Fennell DA, Steele JPC, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005; 47:277-81.
73. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years [see comment]. Eur J Cardio-Thorac Surg 2002;22:298-305.
74. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr 1988;66:607-13.
75. Chan K, Tan KL, Lee HS, Eng P. Malignant mesothelioma: experience at the Singapore General Hospital. Ann Acad Med Singapore 2003;32:388-91.
76. Jubelirer SJ, Garcelon J. Diffuse malignant pleural mesotheslioma at CAMC: a retrospective study of 50 patients. W V Med J 1997;93:120-5.
77. PSSRU. Personal Social Services Research Unit costs. URL: http://www.pssru.ac.uk/. Accessed 11 November 2005.
78. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-5.